Helius Medical Q1 rev $135K (+22% YoY); net loss flat $2.5M; CMS PoNS reimbursement milestone

Solana Co

2024-Q1 EPS reported -$3.08 revenue$135,000

Q1 revenue $135K vs $111K YoY; operating loss $3.4M vs $3.8M, driven by lower professional fees and clinical trial costs.
Net loss $2.5M (both periods); EPS -$3.08 vs -$4.42 in Q1 2023.
Cash $3.6M at March 31; raised $5.6M net in May public offering, extending cash runway into 2025.
Received CMS HCPCS preliminary reimbursement determination for PoNS; final price expected Oct 1, 2024.
Added six sites to stroke registrational program; reached FDA alignment on stroke development plan.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Solana Co reported quarter ended March 31, 2024 results: revenue $135 thousand, net income net loss of $2.5 million, EPS $3.08 per share.

Period: quarter ended March 31, 2024
Revenue: $135 thousand
Net income: net loss of $2.5 million
EPS: $3.08 per share
Result: reported results

Exact text from the filing

Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”). ● Q1 2024 revenue of $135 thousand, compared to $111 thousand in Q1 2023, reflecting increased product sales in both the U.S. and Canada . ● Closed on $6.4 million public offering, raising net proceeds of

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Solana Co filing history →

Source: SEC EDGAR

accession 0001558370-24-007961

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.